|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014582,
umls-concept:C0020823,
umls-concept:C0021757,
umls-concept:C0030705,
umls-concept:C0079490,
umls-concept:C0086960,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0205314,
umls-concept:C0282460,
umls-concept:C0679622,
umls-concept:C1261473,
umls-concept:C1334117,
umls-concept:C1705294
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-4-25
|
|
pubmed:abstractText |
The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
206-10
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11320663-Adolescent,
pubmed-meshheading:11320663-Adult,
pubmed-meshheading:11320663-Aged,
pubmed-meshheading:11320663-Alopecia,
pubmed-meshheading:11320663-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11320663-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11320663-Epirubicin,
pubmed-meshheading:11320663-Female,
pubmed-meshheading:11320663-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11320663-Hematologic Diseases,
pubmed-meshheading:11320663-Humans,
pubmed-meshheading:11320663-Ifosfamide,
pubmed-meshheading:11320663-Male,
pubmed-meshheading:11320663-Middle Aged,
pubmed-meshheading:11320663-Nausea,
pubmed-meshheading:11320663-Sarcoma,
pubmed-meshheading:11320663-Soft Tissue Neoplasms,
pubmed-meshheading:11320663-Vomiting
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
|
|
pubmed:affiliation |
Division of Medical Oncology A, Regina Elena Institute for Cancer Research and Treatment, Via E. Chianesi, 53, 00144 Rome, Italy. lserrone@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
